Literature DB >> 3034842

Non-small cell lung cancer: how oncologists want to be treated.

W J Mackillop, B O'Sullivan, G K Ward.   

Abstract

One hundred and eighteen Canadian doctors who treat lung cancer were asked how they would wish to be managed if they had non-small cell lung cancer. Four clinical situations were described. The doctors' replies to the open-ended management questions were remarkably consistent in view of their diverse backgrounds. Although opinion was divided as to the role of immediate radiotherapy in inoperable cancer, and the role of post-operative radiotherapy following incomplete surgery, there was little controversy as to the role of chemotherapy. Three per cent of doctors wanted adjuvant chemotherapy after surgery for early disease, 9% wanted chemotherapy for advanced disease confined to the chest and 15% wanted chemotherapy for symptomatic metastatic disease. The implications of these results are discussed in the light of current recommendations for treatment of non-small cell lung cancer in the standard North American textbooks of oncology.

Entities:  

Mesh:

Year:  1987        PMID: 3034842     DOI: 10.1016/0360-3016(87)90109-x

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

Review 1.  Is there a role for preference assessments in research on quality of life in oncology?

Authors:  J E Till; H J Sutherland; E M Meslin
Journal:  Qual Life Res       Date:  1992-02       Impact factor: 4.147

2.  Temporal trends and predictors of perioperative chemotherapy use in elderly patients with resected nonsmall cell lung cancer.

Authors:  Jue Wang; Yong Fang Kuo; Jean Freeman; Avi B Markowitz; James S Goodwin
Journal:  Cancer       Date:  2008-01-15       Impact factor: 6.860

3.  Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer.

Authors:  J R Hardy; T Noble; I E Smith
Journal:  Br J Cancer       Date:  1989-11       Impact factor: 7.640

4.  Are treatment strategies of urologic oncologists influenced by the opinions of their colleagues?

Authors:  M J Moore; B O'Sullivan; I F Tannock
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

5.  Factors associated with physicians' recommendations for managing low-risk papillary thyroid cancer.

Authors:  Alexandria D McDow; Benjamin R Roman; Megan C Saucke; Catherine B Jensen; Nick Zaborek; Jamia Linn Jennings; Louise Davies; Juan P Brito; Susan C Pitt
Journal:  Am J Surg       Date:  2020-11-12       Impact factor: 3.125

6.  Oncologists vary in their willingness to undertake anti-cancer therapies.

Authors:  S E Lind; M J DelVecchio Good; C S Minkovitz; B J Good
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

7.  Diagnostic and therapeutic approaches to lung cancer in Canada and their costs.

Authors:  W K Evans; B P Will; J M Berthelot; M C Wolfson
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

8.  Implicit rationing criteria in non-small-cell lung cancer treatment.

Authors:  K Arndt; P Coy; J Schaafsma
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.